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Clinical trialIntroduction: Mandibular osteoradionecrosis (ORN) is a common and serious complication of head and
neck radiotherapy for which there is little reliable evidence for prevention or treatment. The diagnosis
and classification of ORN have been inconsistently and imprecisely defined, even in clinical trials.
Methods: A systematic review of diagnosis and classifications of ORN with specific focus on clinical trials
is presented. The most suitable classification was evaluated for consistency using blinded independent
review of outcome data (clinical photographs and radiographs) in the HOPON trial.
Results: Of 16 ORN classifications found, only one (Notani) appeared suitable as an endpoint in clinical
trials. Clinical records of 217 timepoints were analysed amongst 94 randomised patients in the
HOPON trial. The only inconsistency in classification arose where minor bone spicules (MBS) were appar-
ent, which occurred in 19% of patients. Some trial investigators judged MBS as clinically unimportant and
not reflecting ORN, others classified as ORN based on rigid definitions in common clinical use. When MBS
was added as a distinct category to the Notani classification this ambiguity was resolved and agreement
between observers was achieved.
Discussion: Most definitions and clinical classifications are based on retrospective case series and may be
unsuitable for prospective interventional trials of ORN prevention or treatment. When ORN is used as a
primary or secondary outcome in prospective clinical trials, the use of Notani classification with the addi-
tional category of MBS is recommended as it avoids subjectivity and enhances reliability and consistency
of reporting.
 2016 Elsevier Ltd. All rights reserved.Introduction
Mandibular osteoradionecrosis (ORN) is a common complica-
tion of radiotherapy for head and neck malignancy whereby the
bone undergoes necrosis, becoming exposed. This is usually symp-
tomatic and may cause intra- or extra-oral fistulae, infection, pain
and eventually pathological fracture [1]. The consequences of these
complications include malnutrition, opiate dependency, haemor-
rhage, sepsis, with progressive disfigurement and deterioration in
quality of life. The incidence of head and neck cancer, survival
and proportion receiving radiotherapy are all increasing, in part,due to Human Papillomavirus related cases [2,3]. As such, the ‘at
risk’ population for ORN is increasing and it has justifiably become
a focus for clinical trials.
Classifications of mandibular ORN vary significantly in their
aims but have been developed in order to help the clinician cate-
gorise and manage ORN in routine clinical practice rather than as
endpoints in clinical trials. The emergence of formally conducted
prospective randomized trials addressing ORN, such as HOPON
[4], DAHANCA21 [4], ORN96 [5] & those of Delanian [6], highlights
the requirement for more objective and valid endpoints. This
would facilitate reproducibility across multiple trial sites and val-
idation by independent blinded panels even in the absence of the
patient, irrespective of the treatment arm assigned. Suggested cri-
teria for definition and classification of ORN in clinical trials are
listed in Table 1.
Table 1
Criteria for definition and classification of ORN in clinical trials.
Domain Criteria
a Response Does not assume outcome or response to the use of a
defined prior treatment modality or protocol
b Trend Can be completed at a single time point and without
knowledge of prior ORN or future progression/ prognosis
c Prescription Do not make assumptions about indications for, or
methods of, subsequent treatment
d Blinding Can be readily reproduced for validation by independent
blinded assessor or panel
e Precision Are not subject to subjectivity or vague definitions
f Validation Not dependent on unvalidated patient reported outcomes
or symptom severity
g Exposure Mandates the presence of exposed bone, ie. presence of
radiological changes alone are insufficient to diagnose ORN
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oradionecrosis) addresses the prophylactic benefit of hyperbaric
oxygen in preventing osteoradionecrosis accompanying surgical
procedures to the irradiated mandible. Patients are eligible for
HOPON who require dental extractions in the posterior mandible
or implant placement and are at high risk of ORN following radio-
therapy for head and neck malignancy. In developing the protocol
for the HOPON trial, it has become apparent that a robust classifi-
cation of osteoradionecrosis has not yet been well resolved within
clinical trials.
The aims of this study are to review, refine and validate suitable
classifications of ORN within the setting of clinical trials. A system-
atic review of published classifications of mandibular ORN will be
conducted with specific reference to their suitability as a clinical
trial endpoint, with reference to the criteria listed in Table 1. These
criteria have been assembled as an assumed gold-standard in trials
with osteoradionecrosis as an endpoint. The most suitable method
(s) will subsequently validated using data from the CR-UK HOPON
trial (ISRCTN39634732), focusing on inconsistencies in categoriza-
tion by a blinded independent expert review panel.Table 2
Common diagnostic criteria for mandibular ORN.
Criteria Specified thresholds
Presence of exposed bone [12,13] Minimum dimension 1 cm [13]
Previously irradiated [12–14] (dose not specified in any definition)
Minimum period of exposed bone 2 months [25,26]
3 months [12,27,28]
6 months [13]
Absence of recurrent tumour [12–
14]
(diagnostic criteria not stated in any
definition)Methods
Systematic review
The published literature was reviewed for articles relating to
classification of mandibular osteoradionecrosis 1970–2016.
Pubmed was searched for articles using the terms ‘‘osteoradionec
rosis”, ‘‘mandible”, ‘‘classification”, ‘‘definition” and also with Mesh
term ‘‘Osteoradionecrosis” and Mesh subheadings: ‘‘diagnosis”,
‘‘analysis” and ‘‘classification”. 350 resultant manuscripts in the
English language were hand sorted, and cross-checked by scanning
their reference lists. The criteria for selection were original, inde-
pendent and distinct definitions and classifications of mandibular
osteoradionecrosis. The 13 resultant articles that presented origi-
nal classifications were additionally subject to scrutiny according
to criteria laid out above and this data tabulated (Table S1). Addi-
tionally, the classification of mandibular ORN from the last three
NIH Common Terminology Criteria for Adverse Events (CTCAE)
[7–9] were separately tabulated (Table S2). The classification
method most nearly fitting the criteria established in Table 1,
was used in the second part of the study.
Validation
Anonymised patient records (clinical photographs and radio-
graphs) from 94 patients randomised to the HOPON trial were
reviewed independently by two blinded independent clinicians
(RJS & CB). Cases were classified according to Notani et al. [10]and this was compared with the research site principal investor’s
assessment as annotated on the trial clinical record forms (CRFs).
These records constituted a clinical photograph at 3, 6 and
12 month post-surgery time-points, and accompanying radio-
graphs for the 6 month time-point (and 3 or 12 months, if ORN
was clinically diagnosed). A dedicated software package on the tri-
als unit’s web portal was created so that both clinicians could inde-
pendently access paired clinical photographs and radiographs for
the defined endpoints for each patient. Any cases with discrepan-
cies within the 3 independent assessments, or with any comments
highlighting difficulty in classifying outcome in the free-text were
noted for further analysis. Due to some incomplete data and imma-
turity of all data collection (and exclusion of two ineligible
patients), a total of 217 clinical assessments were reviewed from
a potential total of 336 (65% complete). The photographs and
radiographs from each assessment were made without knowledge
of timing or of which arm of the trial (HBO vs standard therapy) the
patients was in, as the trial is ongoing at the time of writing.
Results
Systematic review: Definition of ORN
Many authors offer a description [11] rather than a definition of
ORN, however a number of subtly differing definitions have been
offered in the published literature. The cited definitions found in
the literature generally appear to originate from three published
versions [12–14]. Harris [12] defines mandibular ORN as ‘‘exposed
irradiated bone that fails to heal over a period of 3 months in the
absence of local tumour”. Marx [13] offers a definition of ‘‘an area
greater than 1cm of exposed bone in a field of radiation that has failed
to show any evidence of healing for at least 6 months”. The definitions
of ORN show some consensus around an area of exposed bone for a
minimum time period in an irradiated field and in the absence of
tumour. The specific extent of exposed bone or time period speci-
fied vary and are presented in Table 2. Store and Boysen [14]
include radiological change without exposed bone within diagnos-
tic criteria, whilst this is specifically excluded by Harris & Marx
[12,13] so this is evidently an area of controversy.
Classification of ORN
Although there was evident overlap between the principles of
classification seen, 13 distinct classifications [10,11,13–23]
(Table S1) were identified between 1983 and 2015 and 3 differing
classifications were offered by CTCAE (Table S2) in 1999, 2006 and
2010. None of the peer reviewed publications were designed with
the stated aim to evaluate treatments under investigation in
prospective clinical trials, and indeed all were evaluated retrospec-
tively from their authors’ own institutional case series. The degree
to which the classifications met the specified criteria varied con-
siderably. As the Notani et al. [10] classification does not rely on
assumptions about response to previous treatment or subsequent
prescription bias, additionally it does not assume knowledge of
Fig. 2.
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for these criteria. As Notani relies on anatomical landmarks and
mandates exposed bone that may be subject to clinical pho-
tographs, it lends itself better to remote and blinded review.
Validation
In most cases the HOPON site principal investigators’ assess-
ment agreed with the blinded clinicians using the Notani et al.
[10] classification. However, in 24 of 217 these endpoint assess-
ments (11.5%), representing 10 of 94 patients (19.1%), there was
discordance. This was due to the presence very small areas of
exposed bone leading to inconsistent recording between Notani 1
ORN and healed outcomes. These cases were subsequently termed
‘‘minor bone spicules” (MBS) and typical cases are illustrated in
Figs. 1–3. Some trial investigators judged MBS as clinically unim-
portant and not reflecting ORN, others classified as ORN based on
rigid definitions in common clinical use.
After identifying the dimensions of bone exposure creating
inconsistencies between clinicians, MBS was subsequently defined
as small spicules (<20 mm2) of bone remaining through mucosal
breaches in the absence of radiographic abnormalities. Other than
the MBS cases, there was 100% agreement between site investiga-
tors and both blinded clinicians as to the diagnosis of ORN, and the
classification of ORN between Notani 1, 2 and 3, which is not con-
sidered further in this manuscript. Of the 187 assessments classed
as healed by the site investigators, 6 were classed as MBS after
review. Of 26 cases classed by site investigators as Notani 1 ORN,
18 were reclassified on review as MBS and one reclassified as
healed. Following adoption of this protocol, and subsequent reclas-
sification with further blinded review, in all 217 time-points and
94 patients, there was 100% convergence between blinded
investigators.Fig. 3.Discussion
We present a refined classification of Mandibular ORN that
incorporates dimensions of exposed bone, fixed anatomical land-
marks and defined time intervals. This reflects the outcome of a
systematic review and detailed internal validation, at least for con-
sistency in categorization to presence and grade of ORN, using the
interim analysis data from a large clinical trial. In this regard, the
classification offers an important advance over those that have
been developed only using retrospective case series, and that areFig. 1. Typical examples of cases classified as Minor Bone Spicules (MBS) as various
clinical endpoints following recruitment to the HOPON trial. Although each case has
exposed bone and incomplete mucosal healing, the total surface area of bone
<20 mm2. Corresponding radiographs are available and do not show radiological
changes consistent with ORN).reliant on subjective assessments, predictions and vague class
boundaries. Scrutiny of those class boundaries employed (which
would include ORN involvement beyond ID nerve, fistula, as well
as 20 mm2 as a cut-off) will understandably invite criticisms of
their arbitrary nature, or the degree to which they are patient-
centered. The authors’ impression that MBS cases are asymp-
tomatic and heal uneventfully will be validated only with the pub-
lication of long term trial outcomes. However, the precise and
measurable criteria suggested offer reproducibility and present a
logical progression of clinical severity that evidently lends itself
to trials better than other available options.
After wider consultation, peer review from the National Cancer
Research Institute H&N Clinical Studies Group, and discussion with
the HOPON Trial Steering Committee, it was felt that MBS should
be used as an additional refinement to Notani class, in order to
reinforce the consistency of reporting for the trial primary end-
point. Thus, an upper size limit is established, e.g. 4  5 mm or
10  2 mm, such that lesions larger than or equal to 20 mm2 would
therefore be classified as ORN and graded in severity according
Notani 1, 2 or 3 depending on radiographic changes, depth of bone
necrosis and other factors. This trial protocol endpoint is illustrated
in Fig. 4, and was subsequently agreed by the HOPON Independent
Data Monitoring Committee. Subsequently the protocol amend-
ment was approved by both Research Ethics Committee (REC)
and the UK Medicines and Healthcare Regulatory Authority
(MHRA).
The application of this refined classification was greatly facili-
tated by the HOPON protocol which mandates clinical measure-
ment and photograph of the largest area of exposed bone in two
Fig. 4. Modified Notani ORN classification incorporating MBS. Not ORN: mucosal
healing, or MBS <20 mm2, or < 6 months. ORN: exposed bone P20 mm2 and P6
months through oral mucosa or facial skin, excluding malignancy, within field of
prior radiotherapy, further classified: Notani 1: ORN confined to alveolar bone.
Notani 2: limited to the alveolar bone and/or above the level of the inferior alveolar
canal. Notani 3: ORN under the lower part of the inferior alveolar canal, with fistula
or bone fracture (Differentiation between Notani 1, 2 and 3 will usually be
dependent on concurrent clinical and radiographic evidence).
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an outcome is reinforced by a comparable approach taken in the
definitions offered by Marx [13], Coffin [16] and Morton [21].
The presumptive classification of MBS as ‘healed’ in all such cases,
will be validated only by subsequent confirmation with longer
term clinical review. Importantly, the use of MBS category may
avoid misleading over-diagnosis of clinically significant ORN as
the main trial outcome. This classification could be used in future
trials of ORN, whether, prevention or therapy, either as an inclu-
sion criterion or endpoint. In the light of the inadequacies of the
CTCAE criteria for ORN classification, it might also have value as
a secondary endpoint in head and neck trials including radiother-
apy where jaw osteoradionecrosis might be an important finding.
The difficulty in classifying ORN raises some issues for the
impact and applicability of the few trials already published in this
field. Marx et al. [24] used the presence of ‘exposed bone’ at the
study socket after 6 months as the primary endpoint for the 1985
ORN prevention after extraction study. Presumably, some of the
ORN outcomes might have reflected only MBS. Similarly, the
ORN96 trial [5] included patients with subtle radiographic changes
but without exposed bone (thus defined as ORN) as eligible for ran-
domisation in the trial. The same trial reported any area of bone
exposure as ORN in its outcome measures, again raising the issue
that different investigators might have had difficulty with allocat-
ing to healed versus ORNwith MBS cases. Almost 20% of patients in
the HOPON trial had MBS which was seemingly clinically insignif-
icant, asymptomatic and with normal radiographs. The reporting of
these cases was highly inconsistent despite site investigators all
being given the same instructions and CRFs. This highlights con-
cerns about trial endpoints in this field commonly not being repro-
ducible, but also with potentially misleading outcomes not
accurately reflecting clinical severity. The difficulty in reporting
and interpreting these trials highlights the importance of consis-
tent, transparency and reproducible classification.
Although there is a paucity of unbiased and reliable evidence for
the management of ORN, adopting reliable and consistently
reported clinical outcome measures will greatly enhance the
impact of future clinical trials. We believe the modified Notaniclassification as described above offers significant advantages in
this regard.Funding
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